Dendreon Corp. DNDN Stock Halted FDA Approval

Shares of Dendreon Corp. (DNDN) have been halted and the company just announced they have received FDA Approval for Provenge.

FDA clears Dendreon's prostate cancer vaccine.

Before the stock halt, Dendreon's stock traded above $45 per share. When DNDN reopens for trading this afternoon, I expect shares to trade between $50-$60.


Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Hot OTC Stocks - Stocks for 2010

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Stock Halted 4/28/09 April 28, 2009

Dendreon ( DNDN ) stock was just halted after completely tanking. I think there was either a leak or a trading glitch but I'm pretty sure all trades will be cancelled one minute prior to the trading halt

I will post the data news on provenge when it comes out but feel free to discuss Dendreon Stock at http://stockstobuy.org

Provenge News

Increased extended survival 4.1 more months ( very good news )

http://investor.dendreon.com/releasedetail.cfm?ReleaseID=380042

Trading probably won't resume until 5:30pm tonight atleast

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Halted - News Pending 4/14/09

Dendreon ( DNDN ) shares are halted tonight, this happened right before 5pm Est. This is a T1 halt which means News Pending.

I will have an update when the news hits! I'm sure this has something to do with their Cancer Drug Provenge.

Update: 5:55pm EST

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

http://investor.dendreon.com/ReleaseDetail.cfm?ReleaseID=376909&Header=News

DNDN Stock will most likely remain halted until the news hits tomorrow. This stock is either headed to $10-$15 or $2 in my opinion. We'll See!

Update 4/14/09: Looks like Provenge data was positive, stock could open at $15-$20

http://finance.yahoo.com/news/Dendreon-cancer-drug-meets-apf-14918879.html

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free